The amendment adds operational clarity as the issuer continues to push for approval amid growing interest in staking-based crypto exchange-traded […] The post CanaryThe amendment adds operational clarity as the issuer continues to push for approval amid growing interest in staking-based crypto exchange-traded […] The post Canary

Canary Capital Refines Staked Injective ETF Proposal

2025/12/18 23:00

The amendment adds operational clarity as the issuer continues to push for approval amid growing interest in staking-based crypto exchange-traded products.

Key Takeaways
  • Canary Capital has amended its SEC filing for a proposed staked Injective ETF, adding operational clarity
  • The ETF would offer spot INJ exposure combined with staking rewards, with BitGo named as custodian
  • Injective’s price remains in a short-term downtrend, with momentum indicators still favoring sellers 

If approved, the fund would hold Injective tokens directly and track spot price performance while generating additional yield through staking. Canary plans to stake all INJ held by the trust via one or more third-party staking providers, though specific partners have not yet been disclosed. The ETF would be listed on Cboe and structured to allow share creation and redemption in large blocks, following standard ETF mechanics.

Custody, Indexing, and Fund Structure

The updated filing outlines how responsibilities would be divided among service providers. BitGo Trust Company has been selected as the digital asset custodian, while U.S. Bancorp Fund Services would act as transfer agent and cash custodian. Paralel Distributors is named as the marketing agent for the trust.

The ETF would track Injective’s price using a dedicated INJ-USD reference index. However, several commercial details remain outstanding, including the fund’s ticker symbol and management fee, which are expected to be disclosed in future amendments if the SEC review progresses.

INJ Price Remains Under Pressure

The regulatory update comes as Injective’s price continues to trend lower in the short term. On the 4-hour chart, INJ has been forming lower highs and lower lows after failing to hold above the $5.80–$6.00 resistance area earlier this month, confirming a clear downtrend.

Momentum indicators reinforce the bearish setup. The Relative Strength Index (RSI) is hovering near the low-30s, signaling weak buying interest and keeping the asset close to oversold conditions without a clear reversal. Meanwhile, the MACD remains below the zero line, with both lines pointing lower, suggesting downside momentum is still dominant.

What Traders Are Watching Next

Trading volume has remained muted during recent bounce attempts, indicating a lack of conviction from buyers. For the near term, traders are watching whether INJ can reclaim the $5.00–$5.20 zone with stronger volume. Failure to do so would likely keep pressure on the downside, with any short-term rebounds viewed as corrective rather than trend-changing.


The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

The post Canary Capital Refines Staked Injective ETF Proposal appeared first on Coindoo.

Market Opportunity
EPNS Logo
EPNS Price(PUSH)
$0.01456
$0.01456$0.01456
-0.54%
USD
EPNS (PUSH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.